Latest Breaking News On - மெலனி சாலமன் - Page 1 : comparemela.com

AbCellera Announces Secondary Private Sale of 11 9 Million Common Shares

VANCOUVER, British Columbia (BUSINESS WIRE) AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), hav.

United statesUnited kingdomBritish columbiaJessica yinglingKevin heyriesCarl hansenExchange commissionAbcellera biologics incBusiness developmentChief executive officerSelling shareholdersRegistration statementPrivate securities litigation reform actFinancial conditionAbcellera biologicsCellera inquiries

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSouth africaUnited kingdomBritish columbiaJessica yinglingKevin heyriesEster falconerEli lillyBo barnhartCarl hansenExchange commissionCompany lillyAbcellera biologics incDefense advanced research projects agencyBusiness development

AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals

AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Mount pleasantNew brunswickUnited statesBritish columbiaJessica yinglingAbcellera biologicsMurray mccutcheonCarl hansenKennedy stewartExchange commissionAbcellera biologics incCorporate developmentDayhu group of companiesDayhu groupManitoba streetsVancouver mayor kennedy

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

Press release content from Business Wire. The AP news staff was not involved in its creation. AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19 March 10, 2021 GMT VANCOUVER, British Columbia (BUSINESS WIRE) Mar 10, 2021 AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for bamlanivimab and etesevimab together, adding to the growing safety and efficacy data that has resulted in the following key milestones accelerating the adoption of the antibody therapy globally:

United kingdomUnited statesBritish columbiaJessica yinglingKevin heyriesEli lillyCarl hansenVaccine research centerCompany lillyAbcellera biologics incNational institute of allergyNational institutes of healthDrug administrationMelinda gates foundationExchange commissionDefense advanced research projects agency

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBritish columbiaJessica yinglingKevin heyriesEli lillyCarl hansenVaccine research centerAbcellera biologics incCompany lillyNational institute of allergyDrug administrationExchange commissionPostmedia network incDefense advanced research projects agencyEuropean union